S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
TEL AVIV & MIAMI - Biobeat Technologies Ltd, a medical device company specializing in wearable cuff-less ambulatory blood pressure monitoring systems, announced Thursday the appointment of Raymond W. Cohen as Chairman of its Board of Directors.
Cohen brings more than four decades of life science industry experience to the Israeli-based company. He previously served as co-founder and CEO of Axonics, Inc., which was acquired by Boston Scientific in November 2024 for $3.7 billion. Earlier this year in March 2025, Cohen, as chairman of SoniVie, Ltd., led the sale of the Israeli clinical stage renal denervation company to Boston Scientific for $600 million.
"Ray’s extensive track record in leading, financing and scaling medical technology companies will be invaluable as we look to capitalize on our unique ambulatory technology," said Arik Ben Ishay, co-founder and CEO of Biobeat, in a press release statement.
Biobeat has developed an FDA-cleared patch device that collects and transmits patient data for analysis of various physiological parameters, including continuous cuff-less ambulatory blood pressure, oxygen saturation, respiration rate, and cardiac output.
Cohen currently serves on several public and private healthcare company boards, including Kestra Medical Technologies (NASDAQ:KMTS), which has a market capitalization of $824 million and demonstrated impressive revenue growth of 115% over the last twelve months. According to InvestingPro analysis, Kestra maintains a FAIR financial health score, with analysts setting price targets between $20-30. Other board positions include InspireMD (NASDAQ:NSPR), and RxSight (NASDAQ:RXST). He also holds chairman positions at Nalu Medical and Archimedes Vascular, while serving as a venture partner with Paris-based Andera Partners and Beijing-based Sherpa Capital Partners.Get access to detailed financial analysis and 6 additional ProTips for KMTS through InvestingPro, which offers comprehensive research reports for over 1,400 US stocks.
The privately held Biobeat, with offices in Israel and Florida, offers technology that provides continuous monitoring through a small patch device that transmits real-time data to a mobile application, presenting an alternative to traditional ambulatory blood pressure monitoring systems. For investors interested in the medical technology sector, InvestingPro provides detailed analysis and investment ideas across the healthcare industry.
In other recent news, Kestra Medical Technologies reported strong growth in its fourth quarter of fiscal year 2025. The company achieved total revenue of $17.2 million, marking a 71% increase from the previous year and surpassing both Stifel and consensus estimates of $15.7 million. Despite a negative earnings per share of -2.21, the company’s impressive revenue gains were driven by a 43% growth in ASSURE prescription volume and enhancements in revenue cycle management. Following these results, Piper Sandler reiterated an Overweight rating with a price target of $27.00, noting that key financial metrics were "very good" despite higher-than-expected operating expenses. Similarly, Stifel maintained its Buy rating and set a price target of $28.00, reflecting confidence in Kestra’s financial performance.
InspireMD recently announced the appointment of Raymond W. Cohen to its Board of Directors. Cohen, a veteran in the medical technology sector, brings over 40 years of experience and was previously the CEO and co-founder of Axonics, Inc. His leadership at Axonics culminated in its $3.7 billion acquisition by Boston Scientific. These developments reflect ongoing strategic moves and financial assessments within both companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.